KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Goodwill (2017 - 2026)

Amneal Pharmaceuticals has reported Goodwill over the past 9 years, most recently at $595.5 million for Q4 2025.

  • For Q4 2025, Goodwill changed 0.33% year-over-year to $595.5 million; the TTM value through Dec 2025 reached $595.5 million, changed 0.33%, while the annual FY2025 figure was $595.5 million, 0.33% changed from the prior year.
  • Goodwill for Q4 2025 was $595.5 million at Amneal Pharmaceuticals, roughly flat from $595.9 million in the prior quarter.
  • Over five years, Goodwill peaked at $602.9 million in Q1 2022 and troughed at $522.8 million in Q1 2021.
  • A 5-year average of $590.4 million and a median of $598.4 million in 2024 define the central range for Goodwill.
  • Biggest five-year swings in Goodwill: rose 15.33% in 2022 and later dropped 0.62% in 2023.
  • Year by year, Goodwill stood at $593.0 million in 2021, then increased by 0.98% to $598.9 million in 2022, then decreased by 0.04% to $598.6 million in 2023, then dropped by 0.2% to $597.4 million in 2024, then fell by 0.33% to $595.5 million in 2025.
  • Business Quant data shows Goodwill for AMRX at $595.5 million in Q4 2025, $595.9 million in Q3 2025, and $597.4 million in Q2 2025.